Samsung BioLogics gauges demand for IPO

South Korea’s biggest conglomerate sets out with ambitious plans to raise as much as $2 billion from the listing of its contract drug unit on the Korean stock market.

Samsung BioLogics gauges demand for IPO

Samsung BioLogics began pre-deal investor education in Seoul on Tuesday for a $1.7 billion to $2 billion initial public offering that will tempt investors with the prospect of a new behemoth and potential industry disrupter from one of the world’s most successful tech companies.

And they will need to believe in the company’s scalability and growth potential given the extremely aggressive valuation attached to the deal, which is being marketed at 96...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Print Edition

FinanceAsia Print Edition